Skip to main content

Patient Support Line 1-800-282-7630 Monday through Friday: 8:00 am – 8:00 pm ET

Image showing a teenage girl floating in pool with her friends swimming around her. Text on image says “How VIJOICE may help.”
VIJOICE is the first and only therapy approved to treat the cause of PROS in children and adults

The safety and effectiveness of VIJOICE were initially assessed in 57 adults and children aged 2 years and older with a PIK3CA-Related Overgrowth Spectrum (PROS) condition, including CLOVES syndrome, MCAP or M-CM, KTS, and FIL. All of the people in this retrospective, real-world study, known as EPIK-P1, had a PIK3CA mutation confirmed by their doctor. In EPIK-P1, those enrolled had follow-up visits for at least 6 months while taking VIJOICE.

Of the original 57 people in EPIK-P1, 48 enrolled in an extension study to evaluate the longer-term safety and effectiveness of VIJOICE. This additional study is known as EPIK-P3, and it assessed people taking VIJOICE for an additional 18 months to 66 months after the initial study.

In the initial study, some experienced a clinically meaningful reduction in the size of overgrowth
27% (10/37) of people taking VIJOICE saw their overgrowth shrink by at least 20% at the 6-month evaluation

These reductions were maintained for at least 6 months in 70% of people

These reductions were maintained for at least 12 months in 60% of people


Most experienced any improvement in overgrowth
74.2% (23/31) of people taking VIJOICE saw any shrinkage in the size of their overgrowth at the 6-month evaluation

Results for other symptoms of PROS

At the 6-month evaluation, after starting treatment with VIJOICE: 
90.9% (20/22) of people experienced less pain. 78.9% (30/38) of people experienced improvements in vascular malformations, or when vessels like veins, arteries, and capillaries grow in abnormal ways. 76.2% (32/42) of people experienced less fatigue. 69% (20/29) of people experienced improvements in limb asymmetry, or when one arm or leg is longer than the other. 55.2% (16/29) of people experienced improvements in disseminated intravascular coagulation, or DIC, a clotting and bleeding condition.
In an extension of the initial study that continued for up to 6 years for each person:
87% (20/23) of people experienced less pain. 92.1% (35/38) of people experienced improvements in vascular malformations, or when vessels like veins, arteries, and capillaries grow in abnormal ways. 100% (42/42) of people experienced less fatigue. 86.2% (25/29) of people experienced improvements in limb asymmetry, or when one arm or leg is longer than the other. 86.2% (25/29) of people experienced improvements in disseminated intravascular coagulation, or DIC, a clotting and bleeding condition.
In the longer-term study, people reported functional improvement
Approximately 81% (38/47) of people taking VIJOICE saw improvements in their ability to do things

The first scale measured a person’s daily activity, physical ability, and ability to care for themselves. An improvement  was defined as a decrease by at least 1 point, and worsening  was defined as an increase by at least 1 point.

The second scale measured a person's ability to perform normal activities of daily living and functional status. An improvement  was defined as an increase by at least 20 points, and worsening  was defined as a decrease by at least 20 points.